2022-RA-1149-ESGO Oxaliplatin-based treatments are currently a valid therapeutic option in heavily pretreated ovarian cancer patientswith hypersensitivity reactions (HRs) to carboplatin in the antiangiogenics and PARPi era
2022-RA-1149-ESGO Oxaliplatin-based treatments are currently a valid therapeutic option in heavily pretreated ovarian cancer patientswith hypersensitivity reactions (HRs) to carboplatin in the antiangiogenics and PARPi era